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cells—including T-lymphocyte effector cells—and 
development of chronic inflammation 5.
One of the greatest risks assumed by individuals 
with i b d  is a heightened susceptibility to colorectal 
cancer (c r c ). Epidemiology studies indicate that the 
duration and severity of chronic colitis are important 
risk factors for c r c  6–8. Because the microbiota play an 
essential role in the development of ulcerative colitis 
and Crohn disease (the two main manifestations of 
i b d ), a close look at the relationship between bacteria 
and c r c  is a must.
EVIDENCE THAT MICROBES ARE INVOLVED 
IN CRC
A tantalizing observation linking bacteria with the 
development of c r c  was made more than a decade 
ago through germ-free technology, in which mice are 
born and maintained in the absence of microorgan-
isms. Dove et al. 9 observed that tumour development 
in germ-free ApcMin (multiple intestinal neoplasia 
allele of the adenomatous polyposis coli gene) 
mice, which serve as a model for human familial 
adenomatous polyposis, was halved as compared 
with that in mice housed under specific pathogen-
free conditions.
More recent findings implicating the microbiota 
as key players in development of c r c  came with the 
discovery of an important communication system be-
tween humans and bacteria. Innate bacteria-sensing 
receptors such as the Toll-like receptor (t l r) and 
the Nod-like receptor alert the host to the presence 
of bacteria 10. Interestingly, deletion of the myeloid 
differentiation factor 88 (myd88) adapter protein, a 
key mediator of the t l r /interleukin 1 (il-1) signalling 
pathway, attenuated polyp formation in the ApcMin 
mouse model 11. These findings support the idea that 
bacteria use t l r-mediated signalling components 
such as myd88 to promote the development of c r c . 
However, because the pro-inflammatory cytokine il-
1β uses myd88 to signal downstream of its receptor, a 
formal demonstration that bacterial signalling factors 
participate in tumour progression is still needed in 
this model.
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The human colon plays host to as many as 15,000–
36,000 bacterial species, amounting to more than 
100 trillion bacteria 1,2. The microbiota and their 
associated prokaryotic genome is an integral part 
of the host and uniquely contributes to various 
biologic processes such as maturation and devel-
opment of the mucosal immune system, metabolic 
capacity, and intestinal epithelial cell proliferation 
and differentiation 3. An international effort is 
currently underway to catalogue the repertoire of 
microorganisms present in the intestines of healthy 
humans and of those with pathologic conditions. 
The human microbiome project—for which the 
U.S. National Institutes of Health has contributed 
more than $110 million—is aiming to determine the 
structure of the microbial community associated 
with the human body and the functions thereby 
served in health and disease 3,4.
Arguably, mapping and comparing the compo-
sition of the microbial community harboured by 
healthy and disease-affected humans represents 
the next frontier in microbiology and medicine. 
Although this field of research is still in its infancy, 
the link between the microbiota and development of 
inflammatory bowel diseases (i b d s) has been estab-
lished in animal models and human patients alike. 
Countless studies have established that an improper 
innate or adaptive host response to microbial con-
stituents leads to unrestricted activation of immune 
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EVIDENCE THAT MICROBES ARE INVOLVED IN 
COLITIS-ASSOCIATED COLON CANCER
A significant risk associated with i b d  is the develop-
ment of c r c , a collective pathophysiologic event called 
colitis-associated colorectal cancer (c a c). The risk of c a c  
developing in individuals affected with ulcerative colitis 
for 30 years or more has been evaluated at 7.6%–18% 8. 
Mouse models of c a c  have been integral to advancing 
an understanding of the effect of the gut microbiota on 
chronic colitis and cancer development.
In the most widely used mouse model of c a c , 
administration of the colon-specific carcinogen 
azoxymethane (a o m) induces initiating genetic 
mutations in the w n t /c t n n b1 (β-catenin) pathway; 
subsequently, administration of dextran sodium 
sulfate (d s s) disrupts the colonic epithelium, induc-
ing chronic colitis 12. Work with this model showed 
that deletion of Tlr4 decreased tumour formation, 
suggesting that bacteria use the receptor to promote 
colorectal carcinogenesis 13. In contrast, deletion of 
Nod1 predisposes to a o m –d s s -induced c a c  14. Because 
t l r4 and n o d1 recognize different microbial spectra 
(extracellular and intracellular respectively), these 
apparently opposite functions could highlight spe-
cific roles for microorganisms in protecting against 
or promoting cancer development. Clearly, establish-
ing the composition of the microbial community 
present in a healthy as compared with a cancer-prone 
intestine may provide insight into the role of bacteria 
in tumorigenesis.
An intriguing observation from studies using 
a o m –d s s -induced c a c  in Tlr4–/– mice is that attenu-
ation of colorectal tumorigenesis occurs without a 
clear concomitant reduction in the severity of inflam-
mation. Interestingly, a similar dissociation between 
inflammation and tumour development was recently 
observed in a o m –d s s -exposed Il6–/– mice 15. In that 
study, the authors demonstrated a strong reduction 
in tumour development in Il6–/– mice despite inflam-
mation being significantly augmented in those mice 
as compared with wild-type mice. These findings 
contrast with the epidemiology data, which indicate 
that severity and duration of chronic colitis directly 
correlates with c r c  risk 7.
The inherent difficulty encountered with the 
a o m –d s s  model in the investigation of inflammation-
driven tumorigenesis lies in its inability to uncouple 
processes elicited by acute wound-healing from those 
of a chronic inflammatory response. This difficulty 
may highlight a limitation of the a o m –d s s  model in 
the study of bacterial/t l r signalling in c a c , because 
this pathway protects against intestinal injury in-
duced by d s s  16. Indeed, although d s s -induced intesti-
nal injury is worsened in Myd88–/– mice, spontaneous 
colitis observed in Il10–/– mice is attenuated in Il10–/–; 
Myd88–/– mice 17,18.
To avoid use of a chronic injury model, researchers 
have substituted the spontaneous Il10–/– mouse model 
of intestinal inflammation for the a o m –d s s  model. 
Work using a combination of this a o m –Il10–/– model 
of c a c  and gnotobiotic techniques recently identified 
a clear role for the microbiota in the development and 
progression of c a c  19. Whereas wild-type mice treated 
with a o m  develop rare, low-grade colonic adenomas, 
Il10–/– mice with normal intestinal microbiota show a 
dramatic increase in c r c  susceptibility, which directly 
correlates with the severity of intestinal inflammation. 
Conversely, a o m -treated Il10–/–; Myd88–/– mice and 
a o m -treated Il10–/– mice housed under germfree condi-
tions fail to develop c a c  19. These findings highlight 
the essential role that the intestinal microbiota play 
in the development of c a c .
From the foregoing studies, it has become clear 
that the microbiota affect colorectal tumour devel-
opment and progression. Certain innate sensors, 
such as n o d1, appear to prevent tumour develop-
ment; others, such as t l r4 and myd88, promote car-
cinogenesis. Further investigation will be required 
to elucidate the nature of these bacterial-mediated 
tumour-suppressing and -promoting signals. Iden-
tification of the microbial communities associated 
with these carcinogenic events will be equally 
important. Finally, key observations made using 
the a o m –Il10–/– model have to be validated in other 
animal models of c a c  before novel paradigms can 
be established.
Although identification of the microbiota as an 
essential factor in colorectal carcinogenesis adds 
complexity to the pathophysiology of this disease, 
this initiative may represent a novel opportunity for 
therapeutic intervention.
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